Mustang Bio (MBIO) Cash from Investing Activities (2017 - 2025)
Mustang Bio (MBIO) posted quarterly Cash from Investing Activities of $1.2 million for Q1 2025, up 3983.33% quarter-over-quarter from -$30000.0 in Q4 2023.
Mustang Bio (MBIO) Cash from Investing Activities (2017 - 2025) Analysis & Trends
Mustang Bio (MBIO) has reported Cash from Investing Activities for 8 consecutive years, with $1.2 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Cash from Investing Activities changed N/A year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.2 million, changed N/A from the prior year.
- Cash from Investing Activities rose to $1.2 million in Q1 2025 per MBIO's latest filing, from -$30000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.9 million in Q3 2023 and bottomed at -$2.4 million in Q2 2021.
- Historically, Cash from Investing Activities has averaged -$105583.3 across 4 years, with a median of -$439000.0 in 2021.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 199.88% — and 2023, when it soared 767.04%.
- Mustang Bio's Cash from Investing Activities stood at -$1.5 million in 2021, then jumped by 71.56% to -$420000.0 in 2022, then surged by 92.86% to -$30000.0 in 2023, then jumped by 3983.33% to $1.2 million in 2025.
- Business Quant data shows MBIO's Cash from Investing Activities at $1.2 million in Q1 2025, -$30000.0 in Q4 2023, and $5.9 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2023 | -30,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Sep 30, 2023 | 5.95 Mn |
| Sep 30, 2023 | 5.95 Mn |
| Jun 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -34,000.00 |
| Dec 31, 2022 | -420,000.00 |
| Dec 31, 2022 | -420,000.00 |
| Sep 30, 2022 | -892,000.00 |
| Sep 30, 2022 | -892,000.00 |
| Jun 30, 2022 | -306,000.00 |
| Jun 30, 2022 | -306,000.00 |
| Mar 31, 2022 | -1.33 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Sep 30, 2021 | -990,000.00 |
| Sep 30, 2021 | -990,000.00 |